Cargando…

Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study

INTRODUCTION: infantile hemangioma is the most common benign tumor in infancy. Currently, oral propranolol is the treatment of choice for infantile hemangioma, but there is no consensus when it comes to its recommended dosage for this condition. Hence this study was conducted to find out the appropr...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasad, Arun, Sinha, Amit Kumar, Kumar, Bindey, Prasad, Abhiranjan, Kumari, Manju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607273/
https://www.ncbi.nlm.nih.gov/pubmed/31303926
http://dx.doi.org/10.11604/pamj.2019.32.155.16760
_version_ 1783432062519214080
author Prasad, Arun
Sinha, Amit Kumar
Kumar, Bindey
Prasad, Abhiranjan
Kumari, Manju
author_facet Prasad, Arun
Sinha, Amit Kumar
Kumar, Bindey
Prasad, Abhiranjan
Kumari, Manju
author_sort Prasad, Arun
collection PubMed
description INTRODUCTION: infantile hemangioma is the most common benign tumor in infancy. Currently, oral propranolol is the treatment of choice for infantile hemangioma, but there is no consensus when it comes to its recommended dosage for this condition. Hence this study was conducted to find out the appropriate dosage of oral propranolol for treatment of infantile hemangioma. METHODS: A prospective study was conducted on 25 patients with infantile hemangioma, who were treated with gradually increasing dose of propranolol starting from a lower dose of 1mg/kg/day. RESULTS: 17/22(76%) patients showed regression of the tumor at the dose of 1- 1.5 mg/kg/d. 5/22(24%) patients were unresponsive to the treatment with the lower dose and they did not respond even with the gradually escalated dose of 3-4 mg/kg/day. CONCLUSION: Propranolol in a lower dose of 1-1.5 mg/kg/day is safe and efficacious in the treatment of infantile hemangioma and the lesions which do not show initial response to the lower dose are unlikely to respond to the higher dose of 3-4 mg/kg/day.
format Online
Article
Text
id pubmed-6607273
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-66072732019-07-12 Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study Prasad, Arun Sinha, Amit Kumar Kumar, Bindey Prasad, Abhiranjan Kumari, Manju Pan Afr Med J Research INTRODUCTION: infantile hemangioma is the most common benign tumor in infancy. Currently, oral propranolol is the treatment of choice for infantile hemangioma, but there is no consensus when it comes to its recommended dosage for this condition. Hence this study was conducted to find out the appropriate dosage of oral propranolol for treatment of infantile hemangioma. METHODS: A prospective study was conducted on 25 patients with infantile hemangioma, who were treated with gradually increasing dose of propranolol starting from a lower dose of 1mg/kg/day. RESULTS: 17/22(76%) patients showed regression of the tumor at the dose of 1- 1.5 mg/kg/d. 5/22(24%) patients were unresponsive to the treatment with the lower dose and they did not respond even with the gradually escalated dose of 3-4 mg/kg/day. CONCLUSION: Propranolol in a lower dose of 1-1.5 mg/kg/day is safe and efficacious in the treatment of infantile hemangioma and the lesions which do not show initial response to the lower dose are unlikely to respond to the higher dose of 3-4 mg/kg/day. The African Field Epidemiology Network 2019-04-08 /pmc/articles/PMC6607273/ /pubmed/31303926 http://dx.doi.org/10.11604/pamj.2019.32.155.16760 Text en © Arun Prasad et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Prasad, Arun
Sinha, Amit Kumar
Kumar, Bindey
Prasad, Abhiranjan
Kumari, Manju
Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study
title Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study
title_full Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study
title_fullStr Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study
title_full_unstemmed Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study
title_short Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study
title_sort individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607273/
https://www.ncbi.nlm.nih.gov/pubmed/31303926
http://dx.doi.org/10.11604/pamj.2019.32.155.16760
work_keys_str_mv AT prasadarun individualizeddosingoforalpropranololfortreatmentofinfantilehemangiomaaprospectivestudy
AT sinhaamitkumar individualizeddosingoforalpropranololfortreatmentofinfantilehemangiomaaprospectivestudy
AT kumarbindey individualizeddosingoforalpropranololfortreatmentofinfantilehemangiomaaprospectivestudy
AT prasadabhiranjan individualizeddosingoforalpropranololfortreatmentofinfantilehemangiomaaprospectivestudy
AT kumarimanju individualizeddosingoforalpropranololfortreatmentofinfantilehemangiomaaprospectivestudy